SlideShare a Scribd company logo
Hepatitis E infections in Hungary,
2002-2014
Ágnes Fehér
National Centre for Epidemiology,
Hungary
1st ECDC Hepatitis E virus expert group meeting
Stockholm, 09-10 December 2015
Introduction
• Viral hepatitis has been notifiable in Hungary since 1950. The
basis of the reports was the clinical diagnosis.
• Serological tests for hepatitis diseases have been available
since mid 1980’s.
• Before 2002, acute viral hepatitis E was rarely diagnosed in
Hungary.
• Electronic surveillance system since 2003.
Background – hepatitis E surveillance in Hungary
Hepatitis E surveillanve is a part of the general communicable
diseases reporting system in Hungary.
• Reporting is compulsory – based on law.
- hepatitis E is on the list of compulsory notifiable
communicable diseases
• Reporters – laboratories / physicians
• Surveillance is aetiology-based
• Case-based: Physicians have to report data of each case within
24 hours of the diagnosis making
- on a paper-based standard case report form - until 2013
- on-line – since 2014.
• Comprehensive and nation-wide: all physicians (GPs,
specialists working in outpatient clinics, physicians working in
hospitals, at emergency service, pathologists, microbiologists)
should report suspected, probable or confirmed cases.
• Passive:
- There is no search for cases, only in the environment of a
known patient
• The EU case definition is used for classifying reported cases.
Main characteristics of hepatitis E surveillance
in Hungary
Hepatitis E surveillance in Hungary
Information from cases
- Case report form – online from the physicians
- Case investigation form
- PH workers ask the patients
- 3 different form (not uniform in all counties)
- Questinaire – pilot version (used not widely)
Laboratory results - from regional and central PH laboratories
and occasionally from private and university labs
There is only one central national database.
- nationwide electronic system for registering and analysing
the data of communicable diseases.
Analysis of hepatitis E surveillance data
Number of hepatitis E cases in Hungary, 2000-2014 (N=604)
0
20
40
60
80
100
120
140 casescases
years
1 Jan 2000 – 5 Dec 2015
• 686 hepatitis E cases were reported
• Sporadic (6 cases to epidemics)
• Case classification:
– Possible : 3
– Probable: 7
– Confirmed: 641 (97,3%)
– No classification: 8
• 67,1% hospitalized
• 5 death (1-1 in 2003, 2008, 2010, 2011, 2012)
• Reported rates per million inhabitants
increased from 1 in 2002 to 9 in 2014.
Analysis of hepatitis E surveillance data
Number of HEV cases and incidence/100000
inhabitants by age-group, 2004-2014 (N=548)
0
2
4
6
8
10
12
14
0
20
40
60
80
100
120
140
160
0-10 10-19 20-29 30-39 40-49 50-59 60-69 70-
cases rate/100000
mean age: 54 years, median: 57 years, range: 4-90 years
cases
rate/100000
Hepatitis E cases by sex in Hungary, 2000-2014
62% was man, male/female = 1,39
0
10
20
30
40
50
60
70
80
2000. 2001. 2002. 2003. 2004. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014.
Male Female
cases
The annual trend increased - incidence rate ratio=1.3; 95%
confidence interval: 1.2-3.4 (Poisson regression).
Distribution of hepatitis E cases and
twelf-month runing avarage,
Hungary, 01.01.2004-12.05.2015, N=659
0
2
4
6
8
10
12
14
16
18
20
Jan
Jun
Nov
Apr
Sep
Feb
Jul
Dec
May
Oct
Mar
Aug
Jan
Jun
Nov
Apr
Sep
Feb
Jul
Dec
May
Oct
Mar
Aug
Jan
Jun
Nov
Apr
Sep
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Cases
Month
Year
Study on trends of hepatitis E infections in
Hungary, 2002-2013
• Retrospective descirtivetopic analysis - of hepatitis E infections
• Calculate incidence rates using census data and analyzed by
time, place and person.
• Determine epidemiological features and trends of hepatitis E
infections
• Examine the changes in the occurrence and characteristics of
hepatitis E cases compaire data 2002-2007 and 2008-2013
• Case definition - persons with clinical diagnosis of acute
hepatitis and anti-HEV IgM positivity.
2002-2007 2008-2013 2002-2013
Number of cases 85 378 463
Incidence rate /100.000 0,14 0,63 0,37
Hospitalization rate/% 96% 70% 83%
Death number 1 4 5
Letality rate/% 1,2 1,1 1,1
Male/% 60% 62% 62%
Male/Female 1,5 1,6 1,6
Avarage/Year 51 55 54
Mean/Year 56 57 57
Min-max/Year 9-84 5-89 5-89
2002-2013: 480 hepatitis E cases were reported, 7 imported cases excluded.
Result of retrospectiv study, 2002-2013
0
5
10
15
20
25
30
35
40
45
50
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2002-2007
2008-2013
Six-years cumulative number
of hepatitis E cases by month, 2002-2013 (N=463)
A second study was performed using new questionaires since
2012. This new reported form have been completted.
No significant relationships between the number of cases and
• food consumption/habits (sausage)
• comorbidity (liver cirrhosis, alcohol dis.)
• certain medical supply no
• possibility of zoonotic infections more data needed
• occupation more data needed
• education no
• distance to the lab no
Retrospectiv study II., 1 Jan 2012. – 30 Jun 2014.
Conclusions
• Last years the number of hepatitis E cases increased
continuously and significantly, although they were
unterreported.
• During 2003-2014 reported rates of hepatitis E cases
increased. The highest rates were among elderly.
• The epidemiological characteristics of hepatitis E cases has not
changed.
• We have to enhance the surveillance to collect information
on risk factors .
• Anti-HEV tests should be possible to use for each county
• Should be evaluate the laboratory capacity, know how many
lab can detect HEV and which method they use to diagnoses.
• Is this continously increase due to improving the diagnostic
capacity or is there any other cause?
Recommendations

More Related Content

What's hot

Hepatitis E in Denmark
Hepatitis E in DenmarkHepatitis E in Denmark
Hepatitis E in Denmark
Cornelia Adlhoch
 
Clinical aspects of hepatitis e virus infection
Clinical aspects of hepatitis e virus infectionClinical aspects of hepatitis e virus infection
Clinical aspects of hepatitis e virus infection
Cornelia Adlhoch
 
HEV surveillance in EU/EEA, 2015
HEV surveillance in EU/EEA, 2015HEV surveillance in EU/EEA, 2015
HEV surveillance in EU/EEA, 2015
Cornelia Adlhoch
 
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Office of HIV Planning
 
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Office of HIV Planning
 
Are EU/EEA countries ready to monitor progress on hepatitis C programmes?
Are EU/EEA countries ready to monitor progress on hepatitis C programmes?Are EU/EEA countries ready to monitor progress on hepatitis C programmes?
Are EU/EEA countries ready to monitor progress on hepatitis C programmes?
European Centre for Disease Prevention and Control
 
Hepatitis E
Hepatitis EHepatitis E
Hepatitis E
ritamarquesdesousa
 
Prevalence of HCV virus genotypes in Albania
Prevalence of HCV virus genotypes in AlbaniaPrevalence of HCV virus genotypes in Albania
Prevalence of HCV virus genotypes in Albania
theijes
 
HEV and Blood Donations
HEV and Blood DonationsHEV and Blood Donations
HEV and Blood Donations
dragoslav domanovic
 
EULabCap methods and indicators: technical updates and survey calendar
EULabCap methods and indicators: technical updates and survey calendarEULabCap methods and indicators: technical updates and survey calendar
EULabCap methods and indicators: technical updates and survey calendar
European Center for Disease Prevention and Control (ECDC)
 
Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...
Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...
Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...
ILRI
 
HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...
HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...
HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...
European Centre for Disease Prevention and Control
 
Experience from Ireland 2014. Stephen Murchan (Ireland)
Experience from Ireland 2014.  Stephen Murchan (Ireland)Experience from Ireland 2014.  Stephen Murchan (Ireland)
Experience from Ireland 2014. Stephen Murchan (Ireland)
European Centre for Disease Prevention and Control (ECDC)
 
Importance and implication of starting HIV treatment early
Importance and implication of starting HIV treatment earlyImportance and implication of starting HIV treatment early
Importance and implication of starting HIV treatment early
European Centre for Disease Prevention and Control
 
How can HIV among men who have sex with men be prevented in Europe? Evidence-...
How can HIV among men who have sex with men be prevented in Europe? Evidence-...How can HIV among men who have sex with men be prevented in Europe? Evidence-...
How can HIV among men who have sex with men be prevented in Europe? Evidence-...
European Centre for Disease Prevention and Control
 
Keating et al Geenius JAIDS 2016
Keating et al Geenius JAIDS 2016Keating et al Geenius JAIDS 2016
Keating et al Geenius JAIDS 2016
Sheila Keating, PhD MSPH
 
Investigating Foodborne Illness Outbreaks With Attorney William Marler
Investigating Foodborne Illness Outbreaks With Attorney William MarlerInvestigating Foodborne Illness Outbreaks With Attorney William Marler
Investigating Foodborne Illness Outbreaks With Attorney William Marler
Bill Marler
 
HIV: Reaching the 90-90-90 targets in europe
HIV: Reaching the 90-90-90 targets in europeHIV: Reaching the 90-90-90 targets in europe
HIV: Reaching the 90-90-90 targets in europe
European Centre for Disease Prevention and Control
 
HIV: epidemiological challenges in Europe
HIV: epidemiological challenges in Europe HIV: epidemiological challenges in Europe
HIV: epidemiological challenges in Europe
European Centre for Disease Prevention and Control
 
Start impaact june 7 2011
Start impaact june 7 2011Start impaact june 7 2011
Start impaact june 7 2011
Phil Boehmer
 

What's hot (20)

Hepatitis E in Denmark
Hepatitis E in DenmarkHepatitis E in Denmark
Hepatitis E in Denmark
 
Clinical aspects of hepatitis e virus infection
Clinical aspects of hepatitis e virus infectionClinical aspects of hepatitis e virus infection
Clinical aspects of hepatitis e virus infection
 
HEV surveillance in EU/EEA, 2015
HEV surveillance in EU/EEA, 2015HEV surveillance in EU/EEA, 2015
HEV surveillance in EU/EEA, 2015
 
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
 
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
 
Are EU/EEA countries ready to monitor progress on hepatitis C programmes?
Are EU/EEA countries ready to monitor progress on hepatitis C programmes?Are EU/EEA countries ready to monitor progress on hepatitis C programmes?
Are EU/EEA countries ready to monitor progress on hepatitis C programmes?
 
Hepatitis E
Hepatitis EHepatitis E
Hepatitis E
 
Prevalence of HCV virus genotypes in Albania
Prevalence of HCV virus genotypes in AlbaniaPrevalence of HCV virus genotypes in Albania
Prevalence of HCV virus genotypes in Albania
 
HEV and Blood Donations
HEV and Blood DonationsHEV and Blood Donations
HEV and Blood Donations
 
EULabCap methods and indicators: technical updates and survey calendar
EULabCap methods and indicators: technical updates and survey calendarEULabCap methods and indicators: technical updates and survey calendar
EULabCap methods and indicators: technical updates and survey calendar
 
Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...
Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...
Risk pathways and prevalence in slaughtered pig blood of Streptococcus suis i...
 
HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...
HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...
HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...
 
Experience from Ireland 2014. Stephen Murchan (Ireland)
Experience from Ireland 2014.  Stephen Murchan (Ireland)Experience from Ireland 2014.  Stephen Murchan (Ireland)
Experience from Ireland 2014. Stephen Murchan (Ireland)
 
Importance and implication of starting HIV treatment early
Importance and implication of starting HIV treatment earlyImportance and implication of starting HIV treatment early
Importance and implication of starting HIV treatment early
 
How can HIV among men who have sex with men be prevented in Europe? Evidence-...
How can HIV among men who have sex with men be prevented in Europe? Evidence-...How can HIV among men who have sex with men be prevented in Europe? Evidence-...
How can HIV among men who have sex with men be prevented in Europe? Evidence-...
 
Keating et al Geenius JAIDS 2016
Keating et al Geenius JAIDS 2016Keating et al Geenius JAIDS 2016
Keating et al Geenius JAIDS 2016
 
Investigating Foodborne Illness Outbreaks With Attorney William Marler
Investigating Foodborne Illness Outbreaks With Attorney William MarlerInvestigating Foodborne Illness Outbreaks With Attorney William Marler
Investigating Foodborne Illness Outbreaks With Attorney William Marler
 
HIV: Reaching the 90-90-90 targets in europe
HIV: Reaching the 90-90-90 targets in europeHIV: Reaching the 90-90-90 targets in europe
HIV: Reaching the 90-90-90 targets in europe
 
HIV: epidemiological challenges in Europe
HIV: epidemiological challenges in Europe HIV: epidemiological challenges in Europe
HIV: epidemiological challenges in Europe
 
Start impaact june 7 2011
Start impaact june 7 2011Start impaact june 7 2011
Start impaact june 7 2011
 

Similar to Hepatitis E infections in Hungary, 2002-2014

Surveillance data on hepatitis B and C in EU/EEA 2014
Surveillance data on hepatitis B and C in EU/EEA 2014Surveillance data on hepatitis B and C in EU/EEA 2014
Surveillance data on hepatitis B and C in EU/EEA 2014
European Centre for Disease Prevention and Control
 
Surveillance of hepatitis B and C in the EU/EEA: 2013 data
Surveillance of hepatitis B and C in the EU/EEA: 2013 dataSurveillance of hepatitis B and C in the EU/EEA: 2013 data
Surveillance of hepatitis B and C in the EU/EEA: 2013 data
European Centre for Disease Prevention and Control
 
Biregional je presentation_surveilance
Biregional je presentation_surveilanceBiregional je presentation_surveilance
Biregional je presentation_surveilance
lankansikh
 
Hepatitis B and C surveillance in the EU/EEA 2015
Hepatitis B and C surveillance in the EU/EEA 2015Hepatitis B and C surveillance in the EU/EEA 2015
Hepatitis B and C surveillance in the EU/EEA 2015
European Centre for Disease Prevention and Control
 
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
European Centre for Disease Prevention and Control
 
Hepatitis B and C surveillance in the EU/EEA, 2016 data
Hepatitis B and C surveillance in the EU/EEA, 2016 dataHepatitis B and C surveillance in the EU/EEA, 2016 data
Hepatitis B and C surveillance in the EU/EEA, 2016 data
European Centre for Disease Prevention and Control
 
EpiBrief_2_2014
EpiBrief_2_2014EpiBrief_2_2014
EpiBrief_2_2014
Mark Muscat
 
Hepatitis E in Ireland
Hepatitis E in Ireland Hepatitis E in Ireland
Hepatitis E in Ireland
Cornelia Adlhoch
 
Current epidemiology of meningococcal disease in the UK and Europe, including...
Current epidemiology of meningococcal disease in the UK and Europe, including...Current epidemiology of meningococcal disease in the UK and Europe, including...
Current epidemiology of meningococcal disease in the UK and Europe, including...
Meningitis Research Foundation
 
Upsurge of chikungunya cases in Uttar Pradesh, India
Upsurge of chikungunya cases in Uttar Pradesh, IndiaUpsurge of chikungunya cases in Uttar Pradesh, India
Upsurge of chikungunya cases in Uttar Pradesh, India
Ahmad Ozair
 
The public health response to increasing syphilis trends in Europe
The public health response to increasing  syphilis trends in EuropeThe public health response to increasing  syphilis trends in Europe
The public health response to increasing syphilis trends in Europe
European Centre for Disease Prevention and Control
 
HIV AIDS Surveillance Report 2015
HIV AIDS Surveillance Report 2015HIV AIDS Surveillance Report 2015
HIV AIDS Surveillance Report 2015
European Centre for Disease Prevention and Control
 
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
European Centre for Disease Prevention and Control
 
Risk factor analysis influenza
Risk factor analysis influenzaRisk factor analysis influenza
Risk factor analysis influenza
Cornelia Adlhoch
 
Surveillance of hepatitis B and C in the EU/EEA – 2017 data
Surveillance of hepatitis B and C in the EU/EEA – 2017 dataSurveillance of hepatitis B and C in the EU/EEA – 2017 data
Surveillance of hepatitis B and C in the EU/EEA – 2017 data
European Centre for Disease Prevention and Control
 
International Journal of Virology & Infectious Diseases
International Journal of Virology & Infectious DiseasesInternational Journal of Virology & Infectious Diseases
International Journal of Virology & Infectious Diseases
SciRes Literature LLC. | Open Access Journals
 
Trends on Health-Care Associated Infections and Infection Control in Estonia ...
Trends on Health-Care Associated Infections and Infection Control in Estonia ...Trends on Health-Care Associated Infections and Infection Control in Estonia ...
Trends on Health-Care Associated Infections and Infection Control in Estonia ...
Kazimierz Murzyn
 
All cause mortality in treated hiv-infected
All cause mortality in treated hiv-infectedAll cause mortality in treated hiv-infected
All cause mortality in treated hiv-infected
Ana Paula Bringel
 
Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...
Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...
Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...
THL
 
Sexually transmitted infections in Europe, 2013
Sexually transmitted infections in Europe, 2013Sexually transmitted infections in Europe, 2013
Sexually transmitted infections in Europe, 2013
European Centre for Disease Prevention and Control
 

Similar to Hepatitis E infections in Hungary, 2002-2014 (20)

Surveillance data on hepatitis B and C in EU/EEA 2014
Surveillance data on hepatitis B and C in EU/EEA 2014Surveillance data on hepatitis B and C in EU/EEA 2014
Surveillance data on hepatitis B and C in EU/EEA 2014
 
Surveillance of hepatitis B and C in the EU/EEA: 2013 data
Surveillance of hepatitis B and C in the EU/EEA: 2013 dataSurveillance of hepatitis B and C in the EU/EEA: 2013 data
Surveillance of hepatitis B and C in the EU/EEA: 2013 data
 
Biregional je presentation_surveilance
Biregional je presentation_surveilanceBiregional je presentation_surveilance
Biregional je presentation_surveilance
 
Hepatitis B and C surveillance in the EU/EEA 2015
Hepatitis B and C surveillance in the EU/EEA 2015Hepatitis B and C surveillance in the EU/EEA 2015
Hepatitis B and C surveillance in the EU/EEA 2015
 
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
HIV infection among persons aged 50 years and over in the EU, 2004–2013: miss...
 
Hepatitis B and C surveillance in the EU/EEA, 2016 data
Hepatitis B and C surveillance in the EU/EEA, 2016 dataHepatitis B and C surveillance in the EU/EEA, 2016 data
Hepatitis B and C surveillance in the EU/EEA, 2016 data
 
EpiBrief_2_2014
EpiBrief_2_2014EpiBrief_2_2014
EpiBrief_2_2014
 
Hepatitis E in Ireland
Hepatitis E in Ireland Hepatitis E in Ireland
Hepatitis E in Ireland
 
Current epidemiology of meningococcal disease in the UK and Europe, including...
Current epidemiology of meningococcal disease in the UK and Europe, including...Current epidemiology of meningococcal disease in the UK and Europe, including...
Current epidemiology of meningococcal disease in the UK and Europe, including...
 
Upsurge of chikungunya cases in Uttar Pradesh, India
Upsurge of chikungunya cases in Uttar Pradesh, IndiaUpsurge of chikungunya cases in Uttar Pradesh, India
Upsurge of chikungunya cases in Uttar Pradesh, India
 
The public health response to increasing syphilis trends in Europe
The public health response to increasing  syphilis trends in EuropeThe public health response to increasing  syphilis trends in Europe
The public health response to increasing syphilis trends in Europe
 
HIV AIDS Surveillance Report 2015
HIV AIDS Surveillance Report 2015HIV AIDS Surveillance Report 2015
HIV AIDS Surveillance Report 2015
 
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
 
Risk factor analysis influenza
Risk factor analysis influenzaRisk factor analysis influenza
Risk factor analysis influenza
 
Surveillance of hepatitis B and C in the EU/EEA – 2017 data
Surveillance of hepatitis B and C in the EU/EEA – 2017 dataSurveillance of hepatitis B and C in the EU/EEA – 2017 data
Surveillance of hepatitis B and C in the EU/EEA – 2017 data
 
International Journal of Virology & Infectious Diseases
International Journal of Virology & Infectious DiseasesInternational Journal of Virology & Infectious Diseases
International Journal of Virology & Infectious Diseases
 
Trends on Health-Care Associated Infections and Infection Control in Estonia ...
Trends on Health-Care Associated Infections and Infection Control in Estonia ...Trends on Health-Care Associated Infections and Infection Control in Estonia ...
Trends on Health-Care Associated Infections and Infection Control in Estonia ...
 
All cause mortality in treated hiv-infected
All cause mortality in treated hiv-infectedAll cause mortality in treated hiv-infected
All cause mortality in treated hiv-infected
 
Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...
Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...
Johanna Takkinen: Operational Collaboration on EU-wide Zoonotic and Foodborne...
 
Sexually transmitted infections in Europe, 2013
Sexually transmitted infections in Europe, 2013Sexually transmitted infections in Europe, 2013
Sexually transmitted infections in Europe, 2013
 

More from Cornelia Adlhoch

Hev in holland 2018
Hev in holland 2018Hev in holland 2018
Hev in holland 2018
Cornelia Adlhoch
 
ECDC_intro_hev_meeting_nov2018
ECDC_intro_hev_meeting_nov2018ECDC_intro_hev_meeting_nov2018
ECDC_intro_hev_meeting_nov2018
Cornelia Adlhoch
 
Intensive care surveillance of influenza, 11 countries, 2009-2016
Intensive care surveillance of influenza, 11 countries, 2009-2016Intensive care surveillance of influenza, 11 countries, 2009-2016
Intensive care surveillance of influenza, 11 countries, 2009-2016
Cornelia Adlhoch
 
EU control strategy for avian influenza
EU control strategy for avian influenzaEU control strategy for avian influenza
EU control strategy for avian influenza
Cornelia Adlhoch
 
Avian influenza in the Netherlands
Avian influenza in the NetherlandsAvian influenza in the Netherlands
Avian influenza in the Netherlands
Cornelia Adlhoch
 
Avian influenza viruses, a serious threat to human health, Bulgaria
Avian influenza viruses, a serious threat to human health, BulgariaAvian influenza viruses, a serious threat to human health, Bulgaria
Avian influenza viruses, a serious threat to human health, Bulgaria
Cornelia Adlhoch
 
Avian influenza detections and management in Bulgaria
Avian influenza detections and management in BulgariaAvian influenza detections and management in Bulgaria
Avian influenza detections and management in Bulgaria
Cornelia Adlhoch
 
Outbreak of avian influenza A(H5N8) in Hungary
Outbreak of avian influenza A(H5N8) in HungaryOutbreak of avian influenza A(H5N8) in Hungary
Outbreak of avian influenza A(H5N8) in Hungary
Cornelia Adlhoch
 
HPAIV H5N8 in Sweden
HPAIV H5N8 in SwedenHPAIV H5N8 in Sweden
HPAIV H5N8 in Sweden
Cornelia Adlhoch
 
Decision cross border health threats intersectoral collaboration
Decision cross border health threats intersectoral collaborationDecision cross border health threats intersectoral collaboration
Decision cross border health threats intersectoral collaboration
Cornelia Adlhoch
 
Hepatitis E in Germany
Hepatitis E in GermanyHepatitis E in Germany
Hepatitis E in Germany
Cornelia Adlhoch
 
Hev risk hide glue and spray dried porcine plasma
Hev risk hide glue and spray dried porcine plasmaHev risk hide glue and spray dried porcine plasma
Hev risk hide glue and spray dried porcine plasma
Cornelia Adlhoch
 
Avian influenza workshop 2015_ecdc
Avian influenza workshop 2015_ecdcAvian influenza workshop 2015_ecdc
Avian influenza workshop 2015_ecdc
Cornelia Adlhoch
 

More from Cornelia Adlhoch (13)

Hev in holland 2018
Hev in holland 2018Hev in holland 2018
Hev in holland 2018
 
ECDC_intro_hev_meeting_nov2018
ECDC_intro_hev_meeting_nov2018ECDC_intro_hev_meeting_nov2018
ECDC_intro_hev_meeting_nov2018
 
Intensive care surveillance of influenza, 11 countries, 2009-2016
Intensive care surveillance of influenza, 11 countries, 2009-2016Intensive care surveillance of influenza, 11 countries, 2009-2016
Intensive care surveillance of influenza, 11 countries, 2009-2016
 
EU control strategy for avian influenza
EU control strategy for avian influenzaEU control strategy for avian influenza
EU control strategy for avian influenza
 
Avian influenza in the Netherlands
Avian influenza in the NetherlandsAvian influenza in the Netherlands
Avian influenza in the Netherlands
 
Avian influenza viruses, a serious threat to human health, Bulgaria
Avian influenza viruses, a serious threat to human health, BulgariaAvian influenza viruses, a serious threat to human health, Bulgaria
Avian influenza viruses, a serious threat to human health, Bulgaria
 
Avian influenza detections and management in Bulgaria
Avian influenza detections and management in BulgariaAvian influenza detections and management in Bulgaria
Avian influenza detections and management in Bulgaria
 
Outbreak of avian influenza A(H5N8) in Hungary
Outbreak of avian influenza A(H5N8) in HungaryOutbreak of avian influenza A(H5N8) in Hungary
Outbreak of avian influenza A(H5N8) in Hungary
 
HPAIV H5N8 in Sweden
HPAIV H5N8 in SwedenHPAIV H5N8 in Sweden
HPAIV H5N8 in Sweden
 
Decision cross border health threats intersectoral collaboration
Decision cross border health threats intersectoral collaborationDecision cross border health threats intersectoral collaboration
Decision cross border health threats intersectoral collaboration
 
Hepatitis E in Germany
Hepatitis E in GermanyHepatitis E in Germany
Hepatitis E in Germany
 
Hev risk hide glue and spray dried porcine plasma
Hev risk hide glue and spray dried porcine plasmaHev risk hide glue and spray dried porcine plasma
Hev risk hide glue and spray dried porcine plasma
 
Avian influenza workshop 2015_ecdc
Avian influenza workshop 2015_ecdcAvian influenza workshop 2015_ecdc
Avian influenza workshop 2015_ecdc
 

Recently uploaded

REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
rightmanforbloodline
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 

Recently uploaded (20)

REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 

Hepatitis E infections in Hungary, 2002-2014

  • 1. Hepatitis E infections in Hungary, 2002-2014 Ágnes Fehér National Centre for Epidemiology, Hungary 1st ECDC Hepatitis E virus expert group meeting Stockholm, 09-10 December 2015
  • 2. Introduction • Viral hepatitis has been notifiable in Hungary since 1950. The basis of the reports was the clinical diagnosis. • Serological tests for hepatitis diseases have been available since mid 1980’s. • Before 2002, acute viral hepatitis E was rarely diagnosed in Hungary. • Electronic surveillance system since 2003.
  • 3. Background – hepatitis E surveillance in Hungary Hepatitis E surveillanve is a part of the general communicable diseases reporting system in Hungary. • Reporting is compulsory – based on law. - hepatitis E is on the list of compulsory notifiable communicable diseases • Reporters – laboratories / physicians • Surveillance is aetiology-based • Case-based: Physicians have to report data of each case within 24 hours of the diagnosis making - on a paper-based standard case report form - until 2013 - on-line – since 2014.
  • 4. • Comprehensive and nation-wide: all physicians (GPs, specialists working in outpatient clinics, physicians working in hospitals, at emergency service, pathologists, microbiologists) should report suspected, probable or confirmed cases. • Passive: - There is no search for cases, only in the environment of a known patient • The EU case definition is used for classifying reported cases. Main characteristics of hepatitis E surveillance in Hungary
  • 5. Hepatitis E surveillance in Hungary Information from cases - Case report form – online from the physicians - Case investigation form - PH workers ask the patients - 3 different form (not uniform in all counties) - Questinaire – pilot version (used not widely) Laboratory results - from regional and central PH laboratories and occasionally from private and university labs There is only one central national database. - nationwide electronic system for registering and analysing the data of communicable diseases.
  • 6. Analysis of hepatitis E surveillance data Number of hepatitis E cases in Hungary, 2000-2014 (N=604) 0 20 40 60 80 100 120 140 casescases years
  • 7. 1 Jan 2000 – 5 Dec 2015 • 686 hepatitis E cases were reported • Sporadic (6 cases to epidemics) • Case classification: – Possible : 3 – Probable: 7 – Confirmed: 641 (97,3%) – No classification: 8 • 67,1% hospitalized • 5 death (1-1 in 2003, 2008, 2010, 2011, 2012) • Reported rates per million inhabitants increased from 1 in 2002 to 9 in 2014. Analysis of hepatitis E surveillance data
  • 8. Number of HEV cases and incidence/100000 inhabitants by age-group, 2004-2014 (N=548) 0 2 4 6 8 10 12 14 0 20 40 60 80 100 120 140 160 0-10 10-19 20-29 30-39 40-49 50-59 60-69 70- cases rate/100000 mean age: 54 years, median: 57 years, range: 4-90 years cases rate/100000
  • 9. Hepatitis E cases by sex in Hungary, 2000-2014 62% was man, male/female = 1,39 0 10 20 30 40 50 60 70 80 2000. 2001. 2002. 2003. 2004. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. Male Female cases
  • 10. The annual trend increased - incidence rate ratio=1.3; 95% confidence interval: 1.2-3.4 (Poisson regression). Distribution of hepatitis E cases and twelf-month runing avarage, Hungary, 01.01.2004-12.05.2015, N=659 0 2 4 6 8 10 12 14 16 18 20 Jan Jun Nov Apr Sep Feb Jul Dec May Oct Mar Aug Jan Jun Nov Apr Sep Feb Jul Dec May Oct Mar Aug Jan Jun Nov Apr Sep 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Cases Month Year
  • 11. Study on trends of hepatitis E infections in Hungary, 2002-2013 • Retrospective descirtivetopic analysis - of hepatitis E infections • Calculate incidence rates using census data and analyzed by time, place and person. • Determine epidemiological features and trends of hepatitis E infections • Examine the changes in the occurrence and characteristics of hepatitis E cases compaire data 2002-2007 and 2008-2013 • Case definition - persons with clinical diagnosis of acute hepatitis and anti-HEV IgM positivity.
  • 12. 2002-2007 2008-2013 2002-2013 Number of cases 85 378 463 Incidence rate /100.000 0,14 0,63 0,37 Hospitalization rate/% 96% 70% 83% Death number 1 4 5 Letality rate/% 1,2 1,1 1,1 Male/% 60% 62% 62% Male/Female 1,5 1,6 1,6 Avarage/Year 51 55 54 Mean/Year 56 57 57 Min-max/Year 9-84 5-89 5-89 2002-2013: 480 hepatitis E cases were reported, 7 imported cases excluded. Result of retrospectiv study, 2002-2013
  • 13. 0 5 10 15 20 25 30 35 40 45 50 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2002-2007 2008-2013 Six-years cumulative number of hepatitis E cases by month, 2002-2013 (N=463)
  • 14. A second study was performed using new questionaires since 2012. This new reported form have been completted. No significant relationships between the number of cases and • food consumption/habits (sausage) • comorbidity (liver cirrhosis, alcohol dis.) • certain medical supply no • possibility of zoonotic infections more data needed • occupation more data needed • education no • distance to the lab no Retrospectiv study II., 1 Jan 2012. – 30 Jun 2014.
  • 15. Conclusions • Last years the number of hepatitis E cases increased continuously and significantly, although they were unterreported. • During 2003-2014 reported rates of hepatitis E cases increased. The highest rates were among elderly. • The epidemiological characteristics of hepatitis E cases has not changed.
  • 16. • We have to enhance the surveillance to collect information on risk factors . • Anti-HEV tests should be possible to use for each county • Should be evaluate the laboratory capacity, know how many lab can detect HEV and which method they use to diagnoses. • Is this continously increase due to improving the diagnostic capacity or is there any other cause? Recommendations